Rocket Pharmaceuticals 株価情報 (NASDAQ: RCKT)

最新ニュース Rocket Pharmaceuticals (NASDAQ:RCKT) 株価情報

Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals Inc

ROCK TECH LINTHIUM INC by Rock Tech Lithium Inc.

Rock Tech Lithium Inc

Goldman Sachs analyst Ryan Nash maintains BankUnited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>) with a Sell and lowers the price target from $38 to $34.

News

Price Target

Analyst Ratings

Goldman Sachs Maintains Sell on BankUnited, Lowers Price Target to $34

Booking Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) shares remained under pressure, despite the company announcing on Tuesday <a href="https://www.benzinga.com/general/travel/25/04/45084896/booking-holdings-shares-slip-despite-better-than-expected-q1-results">upbeat first-quarter guidance</a>.
The announcement came amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
<h1 class="wp-block-heading">Citizens JMP Securities On Booking Holdings</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5dfb69d73513fb0001efda64/nicholas-jones">Analyst </a><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5dfb69d73513fb0001efda64/nicholas-jones">Nicholas Jones</a> maintained a Market Outperform rating, while raising the price target from $5,600 to $5,700.
Booking Holdings reported solid first-quarter results, with revenues of $4.76 billion and adjusted EBITDA of $1.1 billion, beating consensus of $4.60 billion and $850 million, respectively, Jones said in a note. Gross booking value (GBV) came in at $46.7 billion, also above consensus of $46.5 billion, with take rate of 10.2%, he added.
While stating that U.S. demand could be softer than earlier expected due to consumers becoming increasingly cost-conscious, the company indicated that global demand remains stable, the analyst stated. Management's second-quarter guidance came in above consensus, while the full-year guidance reflects that "FX is shifting from an expected ~3 point headwind into a ~2 point tailwind, driving higher nominal 2025 GBV and revenue," he further wrote.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
<h1 class="wp-block-heading">Goldman Sachs On Booking Holdings</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587e33195064ed000173030b/eric-sheridan">Analyst </a><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587e33195064ed000173030b/eric-sheridan">Eric Sheridan</a> reiterated a Neutral rating, while lifting the price target from $4,520 to $4,680.
The company's quarterly results reflected a "broadly solid/stable travel environment," Sheridan said. Booking Holdings is focusing on deeper AI integration, "both as a platform with outside partners and utilizing AI to drive personalization and customization on property for users," he added.
The company is making these investments to remain ready in case the macro environment softens, as it has historically taken share and improved its competitive position during "such shifts in end market demand," the analyst wrote. In the coming quarters, investors are likely to focus on changes in end demand environment and competitive intensity, he further stated.
<h1 class="wp-block-heading">RBC Capital Markets On Booking Holdings</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ecd4830bd9910001845462/brad-erickson">Analyst </a><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ecd4830bd9910001845462/brad-erickson">Brad Erickson</a> reaffirmed an Outperform rating and price target of $5,900.
Despite some softness in the macro environment, Booking Holdings' business remained largely unchanged outside the U.S., Erickson said. The company's room nights grew in the first quarter at the high-end of the guidance range of 5%-7%, he added.
While the second-quarter guidance came in a tad below expectations, at 4%-6%, management indicated global travel demand ex-U.S. remained stable, the analyst stated. Booking Holdings not only has broad global exposure, which helps it mitigate U.S. risks, it has a "relatively larger and more diversified business vs. peers," he further wrote.
BKNG Price Action: Shares of Booking Holdings had declined by 0.21% to $4,898.79 at the time of publication on Wednesday.
Read More: • <a href="https://www.benzinga.com/news/25/04/45045012/sabre-divests-hospitality-arm-tpg-plans-debt-reductioncore-platform-focus">Sabre Divests Hospitality Arm To TPG For $1.1B, Plans Debt Reduction</a>
Photo: Synthetic Messiah/Shutterstock

Analyst Color

Earnings Beats

Reiteration

Travel

Movers

BKNG

Booking Holdings Posts Q1 Beat: Better Positioned Than Peers In A Softening Macro, Analysts Say

Goldman Sachs analyst Jordan Alliger maintains ArcBest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCB#NASDAQ">ARCB</a>) with a Neutral and lowers the price target from $97 to $84.

ARCB

Goldman Sachs Maintains Neutral on ArcBest, Lowers Price Target to $84

Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) shares are trading lower on Wednesday after reporting the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45095569/newell-brands-announces-first-quarter-2025-results" rel="noreferrer noopener">first-quarter earnings report</a>.
The company reported adjusted earnings per share of a one-cent loss, beating the street view of a six-cent loss. Quarterly revenues of $1.57 billion (down&nbsp;5.3% year over year) beat the analyst consensus estimate of $1.54 billion.
Core sales declined 2.1% compared with the prior year period.
The Learning &amp; Development segment generated net sales of $572 million compared with $559 million in the prior year, reflecting core sales growth of 4.2%.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/45098912/caterpillar-faces-lower-q1-results-but-projects-flat-sales-in-2025-or-slight-decline-with-tariff-headwinds" rel="noreferrer noopener">Caterpillar Warns Of $250 Million To $350 Million Tariff Hit After Q1 Profit Miss</a>
The Home &amp; Commercial Solutions segment generated net sales of $812 million, compared with $893 million in the prior year period, reflecting a 5% decline in core sales.
Quarterly normalized gross margin increased to 32.5% compared with 31.0% in the prior year period, while normalized operating margin was 4.5% compared with 4.8% in the previous year period.
In the first quarter, normalized EBITDA was $136 million compared to $152 million in the prior year.
Operating cash outflow was $213 million, compared to $32 million in the prior year period.&nbsp;
At the end of the first quarter, Newell Brands had an outstanding debt of $4.9 billion and cash and cash equivalents of $233 million.
&#8220;Our decision to maintain and invest in a robust and extensive in-house domestic manufacturing base while many of our competitors outsourced or off-shored much of their production capability, positions us well to not just manage tariff related sourcing dislocations, but to ultimately benefit from them,&#8221; said President and Chief Executive Officer Chris Peterson.
Tariff Sensitivity: The most recent reciprocal China tariff of 125% is not included in the company&#8217;s current outlook. The company&#8217;s sensitivity analysis shows that if the 125% tariff rate remains in effect for the full year and is not mitigated, it could reduce Newell Brands&#8217; 2025 normalized EPS by approximately $0.20. However, the company has already identified mitigating actions that it believes would be sufficient to cut this amount in half.
Outlook: Newell Brands reaffirmed its FY2025 adjusted EPS guidance at $0.70–$0.76, above the $0.68 consensus estimate.
The company also maintained its FY2025 sales outlook of $7.28 billion—$7.43 billion, compared to the $7.37 billion estimate.
Newell Brands expects Q2 adjusted EPS of $0.21–$0.24, missing the $0.32 estimate. It sees Q2 sales between $1.931 billion and $1.972 billion, compared with the $1.97 billion estimate.
Price Action: NWL shares are trading lower by 7.45% to $4.79 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45078148/6-stocks-showing-momentum-as-the-market-rebounds" target="_blank" rel="noreferrer noopener">6 Stocks Showing Momentum As The Market Rebounds</a></li>
</ul>
Photo by T. Schneider via Shutterstock

Earnings

Equities

Guidance

Markets

General

Newell Brands Tariff Sensitivity Analysis Shows 125% China Tariff Impact, Stock Tumbles

<a href="https://www.globenewswire.com/Tracker?data=RX14aBC86eNhp_UsxK15P5B57HHSqS_iEDKMctnLlr0dXqqF4z7Q9eQlCzW_kpM3eB1OyENna8uPoZkgmEWUnsdoVWpbBb7CT9086XZ9lHc=">Cosmos Health Inc.</a> ("Cosmos Health" or the "Company'') <a href="https://www.globenewswire.com/Tracker?data=VqRAMfNURVFKgPsLLchWl1sgs-pMnib5E2Lz6B3-9QdKE8afc3L8X_1xeDmpA_QDJEuLgjH2343QlqdqrzwfNhhTyuB0m-QkC3EdjmtnpY8=">(NASDAQ:</a><a href="https://www.benzinga.com/stock/COSM#NASDAQ">COSM</a>), a diversified, vertically integrated global healthcare group engaged in innovative R&amp;D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025.
As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health.

COSM

Cosmos Health CEO Greg Siokas Increases Holdings with $526K Share Purchase

<a href="https://x.com/TonySage7237/status/1917531832897396829" title="https://x.com/TonySage7237/status/1917531832897396829">https://x.com/TonySage7237/status/1917531832897396829</a>

CRML

Tony Sage Executive Chairman of Critical Metals Corp Posts On X "Had a great chat to the Speaker regarding China's monopoly on rare earths and how Tanbreez is the solution."

Stifel analyst Nathan Jones maintains Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Buy and raises the price target from $140 to $141.

Stifel Maintains Buy on Xylem, Raises Price Target to $141

Stifel analyst J. Bruce Chan maintains United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) with a Buy and lowers the price target from $145 to $124.

Stifel Maintains Buy on United Parcel Service, Lowers Price Target to $124

Charles d'Haussy, director of the DYDX Foundation, forecasts a Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price surge to $150,000 by mid-October 2025, followed by a capital rotation into altcoins, driven by clearer U.S. regulations and <a href="https://www.benzinga.com/markets/equities/25/04/45032435/trump-tariffs-prompt-suspension-of-chinese-factory-operations-and-shift-to-new-markets">settling tariff disputes</a>.
What Happened: In an interview with Benzinga, d'Haussy shared his outlook for the cryptocurrency market, emphasizing the impact of the Trump administration's policies and global economic shifts on decentralized finance and crypto derivatives.
D'Haussy predicted that within the next 100 days, the U.S. will see the passage of the <a href="https://www.benzinga.com/content/44656762/sec-says-certain-stablecoins-qualify-as-non-securities-under-new-guidelines">Genius Act and Stablecoin Act</a>, enabling banks to mint and manage stablecoins, thus boosting market liquidity.
He anticipates these regulatory clarifications will stabilize markets, allowing investors to better navigate the tariff-driven economic landscape.
He further noted that tariff disputes will resolve country by country, providing clarity on economic impacts by late summer. 
This, combined with central banks' responses to weakening domestic economies, will trigger a "printing festival" starting with the U.S. Federal Reserve by September 2025. 
"Come September, there's gonna be a printing festival. So the first one to start the dance of the printing festival will be the central banks of the U.S.," d'Haussy said, predicting increased fiat and stablecoin liquidity that will fuel equity and crypto market rallies.
Bitcoin, as the market's flagship asset, will lead the charge, potentially reaching $150,000 by mid-October, according to d'Haussy. 
He expects institutional investors, viewing Bitcoin as a store of value akin to gold, to then rotate profits into altcoins, starting with Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), which he projects could hit $5,000.
"Bitcoin will pump first because the brand is there. Bitcoin is the father of all of us, is the OG," he remarked, highlighting its market dominance.
Also Read: <a href="https://www.benzinga.com/markets/25/04/45026968/bitcoin-fundamentally-decoupled-from-us-tech-stocks-blackrocks-jay-jacobs-says">Bitcoin Fundamentally Decoupled From US Tech Stocks, BlackRock&#8217;s Jay Jacobs Says</a>
Why It Matters: The rotation into altcoins will favor DeFi projects like DYDX, Aave (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/aave/usd">AAVE</a>), Lido (CRYPTO: LIDO), Uniswap (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/uni/usd">UNI</a>), and Morpho, which d'Haussy believes offer tangible business models and clear paths to profitability.
"The one which have a business are mostly in DeFi… you can look at the business and think, okay, this token is underpriced or overpriced," he explained, contrasting these with speculative projects lacking fundamentals.
DYDX, a decentralized exchange (DEX) focused on crypto derivatives, has processed $1.5 trillion in trading volume since 2018 and $200 billion on its proprietary DYDX chain since migrating from Ethereum two years ago. 
Its unique staking model rewards users with USDC from protocol fees, distinguishing it from inflationary staking systems like Ethereum or Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>). 
D'Haussy acknowledged the need for cautious retail engagement, advocating for trust in established brands like DYDX to rebuild confidence. 
He also highlighted DeFi's transparency, noting that platforms like DYDX provide open data accessible to all, including AI trading agents, which are beginning to interact with the platform. 
While optimistic about DeFi's growth, he cautioned that not all altcoins will benefit equally, urging investors to focus on projects with proven business models.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/45026851/bitcoin-etfs-see-442m-daily-inflow-as-btc-hovers-around-94-000">Bitcoin ETFs See $442M Daily Inflow As BTC Hovers Around $94,000</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$AAVE

$BTC

$ETH

$SOL

$UNI

Bitcoin To Hit $150,000 By October, Says DYDX's Charles d'Haussy

Stifel analyst Adam Borg maintains Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) with a Hold and lowers the price target from $45 to $30.

TENB

Stifel Maintains Hold on Tenable Holdings, Lowers Price Target to $30

Stifel analyst Chris O'Cull maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Buy and lowers the price target from $103 to $92.

SBUX

Stifel Maintains Buy on Starbucks, Lowers Price Target to $92

Stifel analyst Shlomo Rosenbaum maintains S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) with a Buy and lowers the price target from $629 to $603.

SPGI

Stifel Maintains Buy on S&P Global, Lowers Price Target to $603

<a href="https://www.youtube.com/watch?v=B-1xpqn6z2o" title="https://www.youtube.com/watch?v=B-1xpqn6z2o">https://www.youtube.com/watch?v=B-1xpqn6z2o</a>

Management

TSLA

President Trump Tells Elon Musk, "You're Invited To Stay As Long As You Want.. You've Done A Fantastic Job"

Stifel analyst Stephen Gengaro maintains ProPetro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PUMP#NYSE">PUMP</a>) with a Buy and lowers the price target from $12 to $11.

PUMP

Stifel Maintains Buy on ProPetro Holding, Lowers Price Target to $11

GameStop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) has outperformed the market over the past 5 years by 68.65% on an annualized basis producing an average annual return of 82.53%. Currently, GameStop has a market capitalization of $12.21 billion. 
Buying $1000 In GME: If an investor had bought $1000 of GME stock 5 years ago, it would be worth $19,927.01 today based on a price of $27.30 for GME at the time of writing.
<h3>GameStop's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746031512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Stifel analyst Matthew Smith maintains Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) with a Buy and raises the price target from $70 to $73.

MDLZ

Stifel Maintains Buy on Mondelez International, Raises Price Target to $73

Stifel analyst Matthew Smith maintains Kraft Heinz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) with a Hold and lowers the price target from $31 to $30.

Stifel Maintains Hold on Kraft Heinz, Lowers Price Target to $30

Stifel analyst Simon Yarmak maintains Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>) with a Buy and lowers the price target from $82.25 to $80.

Stifel Maintains Buy on Equity Residential, Lowers Price Target to $80

Stifel analyst Shlomo Rosenbaum maintains Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) with a Buy and lowers the price target from $307 to $303.

Stifel Maintains Buy on Ecolab, Lowers Price Target to $303

Stifel analyst Nathan Jones maintains Crane (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>) with a Hold and raises the price target from $144 to $150.

Stifel Maintains Hold on Crane, Raises Price Target to $150

Press Releases

Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference

Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference

Comments

Rocket Pharmaceuticals

ニュース

最新ニュース Rocket Pharmaceuticals (NASDAQ:RCKT) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル